Advertisements


We are Sorry, This Page doesn't Exist


FDA Approves $450,000-a-Year Treatment for Rare Disease

Patients who have hereditary transthyretin-mediated amyloidosis, or hATTR, will take the drug for the rest of their lives. Alnylam Phar.....»»

Category: europeSource: fortuneAug 11th, 2018

The danger of "value frameworks" in medicine

In the debate over prescription drug prices, one group is being overlooked: people with rare diseases. The needs of these patients, who rely on specialty medications for their lives and livelihoods,... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkJun 14th, 2018

FDA Approves Migraine Medicine

Doctors say the new migraine drug from Amgen and Novartis can change patients’ lives by lowering the number of migraine days suffered by patients each month......»»

Category: smallbizSource: wsjMay 18th, 2018

No Harm in Reducing Use of Roche Drug for Breast Cancer, Study Says

Treating breast-cancer patients with an expensive Roche drug for six months instead of 12 reduced heart-related side effects without sacrificing effectiveness, a new study found......»»

Category: smallbizSource: wsjMay 16th, 2018

As opioid crisis raged, Insys pushed higher doses of addictive drug and pushed salespeople to ‘own’ doctors

‘It is much easier to take an existing patient and double their units,’ one sales manager wrote, referring to patients as ‘low hanging fruit.’.....»»

Category: topSource: marketwatch6 hr. 17 min. ago

The Daily Biotech Pulse: Eiger"s Lymphoedema Drug Study Fails, Roche"s Sales Rise

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) read more.....»»

Category: blogSource: benzinga12 hr. 16 min. ago

The Daily Biotech Pulse: Eiger"s Lymphoedema Drug Study Fails, Roche"s Sales Rise

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) Endo International PLC (NASDAQ: ENDP) Krys.....»»

Category: earningsSource: benzinga13 hr. 46 min. ago

J&J says putting drug prices in ads may scare away patients

Johnson & Johnson, the world’s most valuable health-care company, says U.S. patients may avoid buying their medications if they see the prices in television ads......»»

Category: topSource: moneycentralOct 16th, 2018

By Adding Patents, Drugmaker Keeps Cheaper Humira Copies Out of U.S.

Cheaper copies of the world’s biggest-selling drug will roll out across Europe after a key European patent for Humira expires, but U.S. patients and insurers will have to wait to access less-expensive versions of the blockbuster drug......»»

Category: smallbizSource: wsjOct 16th, 2018

Cheaper Humira Copy Goes on Sale in Europe, Widening Gap With U.S.

Cheaper copies of the world’s biggest-selling drug will roll out across Europe after a key European patent for Humira expires, but U.S. patients and insurers will have to wait to access less-expensive versions of the blockbuster drug......»»

Category: smallbizSource: wsjOct 16th, 2018

Biosimilar Humira Goes on Sale in Europe, Widening Gap With U.S.

Cheaper copies of the world’s biggest-selling drug will roll out across Europe after a key European patent for Humira expires, but U.S. patients and insurers will have to wait to access less-expensive versions of the blockbuster drug......»»

Category: smallbizSource: wsjOct 16th, 2018

Feds say drugmakers' plan to disclose medicine prices doesn't go far enough

TV drug ads will direct patients to a website with medicine costs, including list prices, out-of-pocket costs and available financial a.....»»

Category: topSource: usatodayOct 15th, 2018

Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

Roche's (RHHBY) MS drug Ocrevus lowers disability progression over five years in relapsing/primary progressive multiple sclerosis with an early initiation of treatm.....»»

Category: smallbizSource: nytOct 10th, 2018

Ionis"s stock surges after Roche collaboration, which could be worth up to $759 million

Shares of Ionis Pharmaceuticals Inc. rallied 4.7% in premarket trade, after the drug discovery company announced a new collaboration deal with Switzerland-based Roche Holding AG , which could be.....»»

Category: topSource: marketwatchOct 10th, 2018

Roche (RHHBY) Presents Encouraging Data on SMA Drug Risdiplam

Roche (RHHBY) reports encouraging data from two pivotal studies -- FIREFISH and SUNFISH -- on ris.....»»

Category: dealsSource: nytOct 4th, 2018

PTC, Roche data add uncertainty to Biogen drug outlook, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 3rd, 2018

Roche Gets FDA Approval for New Formulation of Asthma Drug

Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair. Roche Holding AG RHHBY announced that the FDA has approved expansion prefilled .....»»

Category: dealsSource: nytOct 1st, 2018

Is the possibility of a stroke in your genes?

A landmark international study of DNA samples from 520,000 people around the world, including 67,000 stroke patients, identified 22 new genetic risk factors for stroke.  It is the largest genetic study of stroke to date, and could lead to stroke drug.....»»

Category: topSource: bizjournalsOct 1st, 2018

Portola"s (PTLA) Lymphoma Candidate Gets Orphan Drug Status

Portola's (PTLA) oral Syk/JAK inhibitor, cerdulatinib, secures an orphan drug designation from the FDA for treating patients with peripheral T-ce.....»»

Category: dealsSource: nytSep 26th, 2018

Amarin Surges on Fish-Oil Drug Data

Amarin more than tripled in value after the company said its drug derived from fish oil reduced the risk of heart attacks, strokes and deaths in certain high-risk patients......»»

Category: smallbizSource: wsjSep 24th, 2018